Liang Tang

Liang Tang

Auto-generated profile, based on publicly available information

Liang Tang

Varian Global Translational Science, Varian a Siemens Healthineers Company, Palo Alto, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in New Phytologist
Verified
Journal Article
Closed access
CBCarol Bvindi
Carol Bvindi
SLSanghun Lee
Sanghun Lee
LTLiang Tang
Liang Tang
MMMichael V. Mickelbart
Michael V. Mickelbart
YLYing Li
Ying Li
TMTesfaye Mengiste
Tesfaye Mengiste

9 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
LHLily V.S. Hillson
Lily V.S. Hillson
RMRoss K. McMahon
Ross K. McMahon
NGNorman Galbraith
Norman Galbraith
AMAshley K. McCulloch
Ashley K. McCulloch
CKChia Yew Kong
Chia Yew Kong
CRCampbell S. Roxburgh
Campbell S. Roxburgh
Purpose: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course RT (LCRT; 25 × 1.8 Gy) with concomitant chemotherapy and short-course RT (SCRT; 5 × 5 Gy), typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different RT regimens in LARC. Experimental Design: We conducted a serial sampling study involving patients receiving RT for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA sequencing of tumor biopsies were used to assess local changes. Results: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared with SCRT patients at week 6 (P < 0.0001) and week 12 (P = 0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared with LCRT patients at week 2 (CD8 P = 0.053; FOXP3 P = 0.023) and week 6 (CD8 P = 0.035; FOXP3 P = 0.0016). Conclusions: SCRT is less lymphodepleting and induces more frequent increases in intratumoral T-cell infiltration compared with LCRT. These results are relevant to the field of radiation–immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, in which higher rates of response to RT–immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.

14 October 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SAShuhei Aramaki
Shuhei Aramaki
MDMaxime Dubail
Maxime Dubail
MSMathieu Sertorio
Mathieu Sertorio
MRMd Muedur Rahman
Md Muedur Rahman
MAMst Sayela Afroz
Mst Sayela Afroz
MSMitsutoshi Setou
Mitsutoshi Setou

16 March 2026
Verified
Other
Open access
LHLily V.S. Hillson
Lily V.S. Hillson
RMRoss K. McMahon
Ross K. McMahon
NGNorman Galbraith
Norman Galbraith
AMAshley K. McCulloch
Ashley K. McCulloch
CKChia Yew Kong
Chia Yew Kong
CRCampbell S. Roxburgh
Campbell S. Roxburgh
Waterfall plots representing change in lymphocyte concentrations.

16 March 2026
Verified
Other
Open access
LHLily V.S. Hillson
Lily V.S. Hillson
RMRoss K. McMahon
Ross K. McMahon
NGNorman Galbraith
Norman Galbraith
AMAshley K. McCulloch
Ashley K. McCulloch
CKChia Yew Kong
Chia Yew Kong
CRCampbell S. Roxburgh
Campbell S. Roxburgh
Drug names and dosing schedules

16 March 2026
Verified
Other
Open access
LHLily V.S. Hillson
Lily V.S. Hillson
RMRoss K. McMahon
Ross K. McMahon
NGNorman Galbraith
Norman Galbraith
AMAshley K. McCulloch
Ashley K. McCulloch
CKChia Yew Kong
Chia Yew Kong
CRCampbell S. Roxburgh
Campbell S. Roxburgh
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay